USPTO serial 77302920
BNO 1055
Reviewed by CopyMark Law Group
Reg. 3578606Status 710
- Filing date
- Status date
- Registration date
- Feb 24, 2009
- Examiner
- DIXON, JENNIFER HAZARD
- Law office
- POST REGISTRATION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with BNO 1055?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kenneth F. Florek
Kenneth F. Florek FLOREK & ENDRES PLLC1156 Avenue of the AmericasSuite 600New York, NY 10036-2702Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Vegetable extracts and tinctures in liquid, solid or gaseous form for manufacture of cosmetics, food and nutritional additives; plant extracts, namely, cimicifuga racemosa used in the manufacture of pharmaceutical preparations, bulk pharmaceutical preparations, and raw materials for pharmaceutical preparations | SECTION 8 - CANCELLED | — |
| 003 | Essential oils for use in the manufacture of cosmetics; hair lotions; dentifrices | SECTION 8 - CANCELLED | — |
| 005 | Pharmaceutical preparations for use in the treatment, cure, mitigation or prevention of gingivitis, halitosis, stomatitis, periodontitis, inflammation of the oral cavity and pharyngeal cavity, hypersensitivity of teeth, angina, atherosclerosis, bronchial asthma, circulatory disorders, constipation, diarrhea, heart failure, heart rhythm disorders, high blood pressure, indigestion, insomnia, migraine, motion sickness, nausea, peptic ulcers, vomiting, allergy, gynecological disorders affecting menstruation, sterility, menstrual syndromes, dysmenorrhoea, infertility, genital tract infections, pelvic inflammatory diseases, vaginal discomfort due to menopausal atrophic changes, anatomical abnormalities, neoplasia, breast neoplasm, breast cancer, mamma, mastopathy, mastodynia, premenstrual syndrome, climacteric complaints, breast pain, blood conditions and disorders, blood circulation disorders, high blood pressure, hypertension, pulmonary diseases, heart rhythm disorders, heart failure, urological diseases, sexually transmitted diseases and inflammatory pelvic diseases, menopausal complaints due to therapeutically induced menopause, tamoxifen induced hot flushes of breast cancer survivors, vaginal discomfort due to menopausal atrophic changes, climactic sleep disturbances, depressive moods, osteoprotectio, osteoporosis, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, psycho vegetative disorders, depressive syndrome, anxiety, nervous unrest, peripheral nervous system infections, peripheral nervous system movement disorders, nerve compression syndromes, neuritis, neuralgia and regional pain syndromes, diseases and disorders of the kidney, urological disorders, chronic infections of the bladder, cystitis, pyelonephritis, glomerulonephritis, interstitial nephritis, neprholithiasis, cancer, urolith prophylaxis, dizziness, migraine, depression, inflammations of the upper and lower respiratory organs, sinuses, bronchitis, tonsillitis, arthritis, osteo arthritis, fever, cough, cold, Alzheimer's disease, infection of respiratory tract, infection of urinary tract, urinary obstruction, chronic venous insufficiency, prostate hyperplasia, muscle pains, soft tissue rheumatism, muscularskeletal disease, liver disease, hepatitis, cirrhosis of liver, periodontal diseases and dental caries; pharmaceutical preparations for use as an antidepressant, diuretic, hypnotic, sedative, stimulant, and tranquilizer; hemorrhoidal ointment, laxative, nasal decongestant capsules, nasal spray preparations, non-narcotic analgesics, throat lozenges; menstruation circulation regulating tablets; hormone preparations, hormone replacement medication; pharmaceutical preparations for sensory organs, namely, for use in ophthalmology, otolaryngology and dermatology; pharmaceutical preparations for regulation and strengthening of the immune system; pharmaceutical preparations for treating temporary relief of occasional minor irritation, pain, sore mouth, sore gums, sore throat, pain associated with canker sores, pain due to minor irritation or injury of the mouth and gums, pain due to minor dental procedures, pain due to minor irritations caused by dentures or orthodontic appliances, sore gums due to teething in infants and children four months of age and older; pharmaceutical products, namely, medicated dental, gum and mouth washes, medicated dental, gum and mouth rinse, medicated toothpastes, medicated oral-care gels, medicated dental gels, medicated lozenges, cough lozenges, medicated chewing gum, medicated gels and fluids in the nature of dental bleaching gels, gum balms, medicated dental floss, medicated dental tapes, medicated dental ribbons, medicated teeth whitener gels, medicated toothpicks, fluoride chewing gum and chewable tablets for disclosing dental plaque and tartar; preparations for dental purposes, namely, plaque disclosing reagents, periodontal diagnostic reagents for medical purposes for detecting derivatives from periodontal bacteria, caries, diagnostic reagents for detecting derivatives from caries-causal bacteria and medicines for the prevention and treatment of periodontal diseases, dental caries, canker sores, cold sores, mucositis and oral and tongue cancers; medicated mouth sprays and desensitizers; plant extracts for veterinary and pharmaceutical purposes; sanitary preparations for medical use; sanitary preparations for hygiene, namely, antiseptics, oral antiseptics, disinfectants for hygiene purposes; sanitary preparations for the treatment, cleaning and protection of the skin; dietary supplements in the form of tablets, drops, capsules, extract preparations, balms or in liquid form, containing plant extracts; dietetic substances adapted for medical use in the form of tablets, drops, capsules, extract preparations, balms or in liquid form; food for medically restricted diets, food for diabetics, food supplements containing plant extracts, food supplements derived from plants or plant extracts, all aforesaid goods in the form of tablets, drops, capsules, extract preparations, balms or in liquid form; vitamin and mineral supplements; food supplements, namely, herbal teas for medicinal purposes and medicinal teas; nutritional additives for medical purposes for use in foods and dietary supplements for human consumption; dietetic food supplements; dietary supplements; food supplements and dietary food supplements; mineral food supplements, food supplements based on amino acids, minerals and/or trace elements; food supplements; medical plasters; materials for dressings, namely, gauze and bandages; all purpose disinfectants; material for stopping teeth; dental wax | SECTION 8 - CANCELLED | — |
| 030 | Plant extracts, tinctures and flavourings in liquid, solid or gaseous form or non-nutritional purposes in food used as flavorings and seasonings, herbal teas for food purposes; plant extracts used as flavouring in liquid, solid or gaseous form for foodstuffs, food supplements and food; foods and dietetic foods, namely, ready to eat cereal derived food bars; flavourings in liquid, solid or gaseous form for the manufacture of edible cosmetics and food; herbal teas | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Bionorica AG
- Other trademarks owned by Bionorica AG
- Other trademarks owned by Bionorica AG
- Other trademarks in Class 001
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 030
- Similar marks named BNO 1055
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 25, 2015 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Apr 27, 2010 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 28, 2009 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Apr 23, 2009 | PLGL | ASSIGNED TO PARALEGAL | — |
| Mar 30, 2009 | AMD7 | SEC 7 REQUEST FILED | — |
| Mar 30, 2009 | PAPER RECEIVED | — | |
| Feb 24, 2009 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 9, 2008 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 25, 2008 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Nov 25, 2008 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Nov 19, 2008 | NPUB | NOTICE OF PUBLICATION | — |
| Nov 6, 2008 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Oct 2, 2008 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 29, 2008 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Sep 29, 2008 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 29, 2008 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 29, 2008 | CPRA | PRIORITY ACTION MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Sep 29, 2008 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Sep 15, 2008 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Aug 29, 2008 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Aug 20, 2008 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jul 22, 2008 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 4, 2008 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Jun 4, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 4, 2008 | ALIE | ASSIGNED TO LIE | — |
| Jun 2, 2008 | PAPER RECEIVED | — | |
| Dec 11, 2007 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 10, 2007 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 10, 2007 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 17, 2007 | NWAP | NEW APPLICATION ENTERED | — |